TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04368936

Intervention type: GENETIC
Intervention: Isolated DNA, Real Time PCR
Description: We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele.

Intervention type: GENETIC
Intervention: Isolated DNA, Real Time PCR
Description: We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele.

Intervention type: GENETIC
Intervention: Isolated DNA, Real Time PCR
Description: We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele.

Intervention type: GENETIC
Intervention: Isolated DNA, Real Time PCR
Description: We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele.

Intervention type: GENETIC
Intervention: Isolated DNA, Real Time PCR
Description: We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele.

Intervention type: GENETIC
Intervention: Isolated DNA, Real Time PCR
Description: We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele.
Study: NCT00667784

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
Study: NCT03892889

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Abilify MyCite®
Description: Combination product of aripiprazole tablet embedded with sensor and wearable patch.
Study: NCT02453789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alginate oligosaccharide
Description: Inhalation of dry powder for inhalation (DPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01491477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™
Description: Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™
Description: Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
Study: NCT04260191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 910
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 910
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 910
Description: IV Infusion
Study: NCT02451345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized risk model+website+coaching intervention
Description: A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care.
Study: NCT01804959

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vivomixx probiotics
Study: NCT02448303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Study: NCT00630877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin extended-release (NER)
Description: Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin extended-release (NER)
Description: Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin extended-release (NER) placebo
Description: Tablets administered once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Description: Tablets (325 mg) administered once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) placebo
Description: Tablets administered once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) placebo
Description: Tablets administered once daily for 6 weeks
Study: NCT03616210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protective ventilation
Description: Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
Study: NCT04599881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTR-01
Description: IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
Study: NCT02657850

Intervention type: OTHER
Intervention: non- head and neck self reporting
Description: non- head and neck patient self reports dysphagia symptoms

Intervention type: OTHER
Intervention: head neck self reporting
Description: head and neck patient self reports dysphagia symptoms

Intervention type: OTHER
Intervention: provider reporting
Description: provider reports on head and neck cancer patients' dysphagia symptoms
Study: NCT06454513

Intervention type: PROCEDURE
Intervention: general anesthesia
Description: Different anesthesia methods
Study: NCT01963689

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention Group 2
Description: Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group 1
Description: Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group 3
Description: Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
Study: NCT01428492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
Study: NCT01406769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical vulvectomy or radical local excision
Study: NCT01818219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Records of EADI derived parameters
Study: NCT00486213

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pyridoxine hydrochloride
Description: Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
Study: NCT01428492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
Study: NCT02661906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKY
Description: Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SKY
Description: Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
Study: NCT01690403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine (M000473)
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine (M000473)
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine (M000473)
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFZ EMT TDF
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFZ EMT TDF
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFZ EMT TDF
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT04946513

Intervention type: OTHER
Intervention: Muscle volumes were measured on pre- and postoperative MRI scans.
Description: Muscle volumes were measured on pre- and postoperative MRI scans.
Study: NCT02294292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Ligation
Study: NCT03757559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 100 micrograms
Description: Tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 400 micrograms
Description: Tablets were taken under fasted conditions with non-carbonated water.
Study: NCT00486213

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03757559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 400 micrograms
Description: Tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone hydrochloride 4 milligrams
Description: Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone hydrochloride 4 milligrams
Description: Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching hydromorphone
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Study: NCT01035593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plasmapheresis and IVIG
Description: Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant C1 inhibitor
Description: 100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
Study: NCT01779349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Urine Vibration Holter
Description: each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study
Study: NCT03757559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching hydromorphone
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Study: NCT03930056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Brace II
Description: Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Care KAFO intervention
Description: Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
Study: NCT03327701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
Study: NCT03757559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching hydromorphone
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching hydromorphone
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching hydromorphone
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Study: NCT03327701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benralizumab
Description: Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
Study: NCT03757559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching cebranopadol
Description: Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching cebranopadol
Description: Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
Study: NCT03757559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching cebranopadol
Description: Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching cebranopadol
Description: Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
Study: NCT06054646

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amnion collagen
Description: A collagen extract sourced from the human amniotic membrane

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: Autologous preparation of PRP
Study: NCT01543256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex™ Biliary RX Fully Covered Stent System RMV
Description: Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Plastic Stent Per Investigator preference
Description: Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
Study: NCT01764100

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).